Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › GOSS

Gossamer Bio

GOSS Rare disease Lead: NDA Submitted 10 Biotech Distilled articles ↓ 50 filings & releases ↓ Cash $41.1M (Jun 30, 2026) ↓ 10 verdicts ↓ 1 timing quote ↓
Cardiovascular Small Molecule

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. RT234 Inhaled Vardenafil trial start2027RT234 Inhaled Vardenafil trial start, 2027, routine
  2. 2030 Notes corporate updateMar 2, 20272030 Notes corporate update, Mar 2, 2027, routine
  3. seralutinib PAH FDA approval3Q 2027seralutinib PAH FDA approval, 3Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Capital (as filed)

Cash
$41.1M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$15.9M Jun 30, 2026
Operating cash flow
−$39.4M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$57.0M cash, runway into 2028 per the update of Aug 21, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (10)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on Gossamer Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-02-03 Watch Gossamer Bio (GOSS): Scientific Deep Dive for Seralutinib The biological mechanism is sound but clinical execution risk is high, relying on a post-hoc subgroup analysis from a failed Phase 2; wait for PROSERA results before taking a position.
  2. 2026-03-01 Avoid UPDATE: Gossamer Bio (GOSS) - The Enrichment Trap Springs Shut PROSERA failed its primary endpoint confirming the Phase 2 subgroup signal was a statistical artifact; with Chiesi gone, pipeline halted, and $198M in convertible debt, the equity is functionally worthless.
  3. 2026-03-22 Avoid UPDATE: Gossamer (GOSS) - The Anatomy of a Biotech Death Spiral Going concern qualification, closed capital markets, and $198M debt wall make Gossamer a distressed financial vehicle with no viable drug development path.
  4. 2026-05-15 Avoid UPDATE: Gossamer Bio (GOSS) - The Zombie Files Its Q1, and a Class Action Arrives Cash runway ends before the $198M debt matures, the NDA Hail Mary has very low base-rate odds, and a class action adds further liability ahead of equity holders.
  5. 2026-05-19 Avoid UPDATE: Gossamer Bio (GOSS) - The Debt Wall Comes Down, and So Does the Equity The debt-for-equity exchange triples the float in noteholder hands, forces a mandatory $100-150M equity raise, and leaves common shareholders diluted into a sliver with no realistic recovery path.
  6. 2026-07-28 Avoid UPDATE: Gossamer Bio (GOSS) - The Zombie Gets a Filing Path Despite debt reduction and a non-frivolous NDA pathway, the drug's effect size is one-third of Winrevair's, cash is burning fast against a covenant, and the equity faces further mandatory dilution.
  7. 2026-08-14 Avoid UPDATE: Gossamer Bio (GOSS) - The Debt Wall Didn't Move to 2030. It Moved to March. The springing maturity clause means the $65.2M of 2030 notes accelerate to March 2, 2027 if the $18.9M stub isn't retired, creating a near-term solvency cliff the July update underweighted.
  8. 2026-08-22 Watch UPDATE: Gossamer Bio (GOSS) - Somebody Just Underwrote the Hail Mary A $250M structured placement with $150M committed capital defuses the March 2027 solvency detonator and extends runway into 2028, but the drug's effect size and heavy dilution ahead mean this is a funded option on a low-probability approval, not a buy.
  9. 2026-09-09 Watch UPDATE: Gossamer Bio (GOSS) - The Ratio Lands at 1-for-80 The 1-for-80 reverse split with authorized shares cut to 50M makes the dilution ceiling visible and the stock institutionally accessible, but the drug's effect size and unresolved 2027 stub mean the approval odds are unchanged.
  10. 2026-09-23 Watch UPDATE: Gossamer Bio (GOSS) - The NDA Is In. The Clock Is Running. NDA submission was confirmed on schedule and the FDA filing decision should land before the $125M tranche deadline, but the drug's effect size and approval odds are unchanged and the stock drifting below the tranche floor worsens dilution math.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (50)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 15, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

18 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)